Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
COM-902 by Compugen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
COM-902 by Compugen for Epithelial Ovarian Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase...
COM-902 by Compugen for Peritoneal Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...
COM-902 by Compugen for Metastatic Colorectal Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
COM-902 by Compugen for Fallopian Tube Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...
COM-902 by Compugen for Non-Small Cell Lung Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
COM-902 by Compugen for Non-Small Cell Lung Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
COM-902 by Compugen for Fallopian Tube Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...
COM-902 by Compugen for Metastatic Colorectal Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
COM-902 by Compugen for Peritoneal Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...
COM-902 by Compugen for Epithelial Ovarian Cancer: Likelihood of Approval
COM-902 is under clinical development by Compugen and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase...